QNTM
Quantum BioPharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$2.41
−2.43%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$2.50
From 52W high−83.57%
Volume63123.00
Market cap$19.49M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$2.50
From 52W high
−83.57%
Volume
63123.00
Market cap
$19.49M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.4x
P/E (TTM)
—
RSI (14)
31.7
MomentumView details →
1D Return
−2.43%
YTD Return
−65.34%
SummaryUpdated Jun 1, 2026
Quantum BioPharma Ltd. (NASDAQ:QNTM) is a Canadian biopharmaceutical company headquartered in Toronto that focuses on developing treatments for challenging neurodegenerative, inflammatory, and metabolic disorders, as well as alcohol misuse disorders. Originally founded as FSD Pharma Inc., the company rebranded to Quantum BioPharma Ltd. in August 2024 to better reflect its strategic focus on biopharmaceutical development. The company operates as a clinical-stage biotech firm with drug candidates in various stages of development, maintaining a dual business model that combines pharmaceutical research with strategic real estate investments.
Similar companies
Latest newsMore news →
Quantum BioPharma signed a contract with Thermo Fisher Scientific's clinical research business to implement the Phase 2 Lucid-MS trial of its neuroprotective therapy in multiple sclerosis.14d agoUnbuzzd Wellness, a licensee of Quantum BioPharma, appointed Zappy as its CEO.26d agoQuantum BioPharma Ltd. received FDA clearance to begin clinical trials for a multiple sclerosis treatment.41d ago